Zepp Health Corp 6-K, filed Sep 2, 2026

Zepp Health Corp (ZEPP)

6-K 2026-09-02 For: 2026-09-02

Added on September 02, 2026

About this 6-K

Zepp Health Corp filed this 6-K on September 2, 2026.

	·	Revenue reached US$63.5 million, representing year-over-year growth of 6.9%.
	·	Gross margin was 37.4%, an increase of 1.2 percentage points from the second quarter of 2025. The improvement was primarily driven by a more favorable product mix and growing contribution from higher-value products, partially offset by higher memory and other component costs.
	·	Net loss attributable to Zepp was US$11.3 million, compared with US$7.7 million in the same period of 2025. The benefits of higher revenue and improved gross margin were offset by foreign-exchange headwinds and increased investment in research and development, marketing and brand building.
	·	As of June 30, 2026, cash and cash equivalents and restricted cash totaled US$106.3 million, compared with US$95.3 million a year earlier and US$103.2 million as of March 31, 2026, primarily reflecting improved working-capital management.
	·	During the quarter, the Company launched new products or expanded its portfolio across multiple major product families, including professional running, Hybrid Training, entry-level smartwatches and screen-free fitness and health wearables.

	As of December 31,		As of June 30,
	2025		2026
	US$		US$
Assets
Current assets:
Cash and cash equivalents		57,046		69,661
Restricted cash		55,887		36,608
Accounts receivable, net		66,908		75,537
Amounts due from related parties		6,665		7,051
Inventories, net		72,756		62,434
Prepaid expenses and other current assets		34,263		31,221
Total current assets		293,525		282,512

Property, plant and equipment, net		5,662		5,449
Intangible asset, net		13,611		12,808
Goodwill		9,581		9,581
Long-term investments		220,047		227,821
Deferred tax assets		15,743		16,024
Amount due from related parties, non-current		991		-
Other non-current assets		3,718		3,346
Operating lease right-of-use assets		1,958		2,128
Total assets		564,836		559,669

	For the Three Months Ended June 30,
	2025			2026
	US$			US$
Revenues		59,406			63,525
Cost of revenues		(37,915	)		(39,797	)
Gross profit		21,491			23,728
Operating expenses:
Selling and marketing		(12,050	)		(18,288	)
General and administrative		(4,384	)		(6,200	)
Research and development		(11,157	)		(11,545	)
Total operating expenses		(27,591	)		(36,033	)
Operating loss		(6,100	)		(12,305	)

Other income and expenses:
Interest income		295			465
Interest expense		(1,245	)		(1,679	)
Gain from fair value change of long-term investments		3			3,040
Other income/(expense), net		56			(14	)
Loss before income tax and loss from equity method investments		(6,991	)		(10,493	)
Income tax expenses		(242	)		(114	)
Loss before loss from equity method investments		(7,233	)		(10,607	)
Net loss from equity method investments		(507	)		(723	)
Net loss attributable to Zepp Health Corporation		(7,740	)		(11,330	)

Basic and diluted net loss per share attributable to Zepp Health Corporation		(0.03	)		(0.04	)

Basic and diluted net loss per ADS (16 ordinary shares equal to 1 ADS)		(0.49	)		(0.72	)

Weighted average number of shares used in computing basic and diluted net loss per share		253,536,783			253,356,305

	For the Six Months Ended June 30,
	2025			2026
	US$			US$
Revenues		97,943			115,072
Cost of revenues		(62,091	)		(71,907	)
Gross profit		35,852			43,165
Operating expenses:
Selling and marketing		(25,891	)		(34,928	)
General and administrative		(10,902	)		(13,555	)
Research and development		(23,534	)		(24,679	)
Total operating expenses		(60,327	)		(73,162	)
Operating loss		(24,475	)		(29,997	)

Other income and expenses:
Interest income		876			796
Interest expense		(2,603	)		(3,333	)
(Loss)/gain from fair value change of long-term investments		(122	)		3,117
Other income/(expense), net		60			(66	)
Loss before income tax and loss from equity method investments		(26,264	)		(29,483	)
Income tax expenses		(352	)		(328	)
Loss before loss from equity method investments		(26,616	)		(29,811	)
Net loss from equity method investments		(865	)		(1,162	)
Net loss		(27,481	)		(30,973	)
Less: Net loss attributable to noncontrolling interest		-			-
Net loss attributable to Zepp Health Corporation		(27,481	)		(30,973	)

Basic and diluted net loss per share attributable to Zepp Health Corporation		(0.11	)		(0.12	)

Basic and diluted net loss per ADS (16 ordinary shares equal to 1 ADS)		(1.72	)		(1.95	)

Weighted average number of shares used in computing basic and diluted net loss per share		254,965,539			253,533,249

	As of December 31,		As of June 30,
	2025		2026
	US$		US$
Liabilities
Current liabilities:
Accounts payable		80,768		87,979
Advance from customers		76		56
Amounts due to related parties		654		396
Accrued expenses and other current liabilities		37,527		37,182
Income tax payables		366		249
Notes payable		111,725		111,672
Short-term bank borrowings		55,728		76,842
Total current liabilities		286,844		314,376
Deferred tax liabilities		2,673		2,754
Long-term borrowings		59,475		56,397
Other non-current liabilities		209		108
Non-current operating lease liabilities		1,102		1,066
Total liabilities		350,303		374,701

	As of December 31,			As of June 30,
	2025			2026
	US$			US$
Equity
Ordinary shares		26			26
Additional paid-in capital		280,676			282,326
Treasury stock		(16,153	)		(17,568	)
Accumulated retained earnings/(loss)		(11,450	)		(42,423	)
Accumulated other comprehensive loss		(38,566	)		(37,393	)
Total equity		214,533			184,968
Total liabilities and equity		564,836			559,669